Detailed Narrative
Q4 FY26 Performance Overview and Geopolitical Impact
Sanjivani Paranteral Limited reported Q4 FY26 consolidated revenue of INR 132.1 million and EBITDA of INR 21.73 million, with an EBITDA margin of 15.74%. The standalone revenue was INR 105.1 million, yielding an EBITDA of INR 16.58 million and a PAT of INR 9.4 million. The quarter's performance was significantly impacted by geopolitical conflicts in the Middle East during March 2026, which disrupted export operations and led to a year-on-year decline in revenues.
New Growth Platforms: IV Fluid and Nutraceuticals Traction
The new IV fluid infusion plant in Pune demonstrated encouraging traction, with its revenue contribution increasing from INR 1.2 crore in Q3 FY26 to INR 2.7 crore in Q4 FY26. Management expects sequential improvement, targeting 40-45% utilization in Q1 FY27, rising to 70% by Q4 FY27, and an annual revenue of INR 60-65 crores at full capacity. The Prague-based nutraceutical venture, where Sanjivani holds a 45% stake, is also building commercial transactions and is expected to contribute PAT in FY27 after no contribution in FY26.
FY27 Outlook and Margin Expectations
The company is optimistic for FY27, anticipating stronger momentum across all three verticals. For the base business, a revenue target of INR 80-85 million is set, with expected EBITDA margins of 15.5-16.5%. The IV business is projected to achieve EBITDA margins of 17-18% on an annualized basis. Growth is expected from injectables (10-12%), tablets (7-8%), and nutraceuticals (8-9%), driven by product portfolio expansion and market diversification.
Raw Material Costs, Logistics, and Pricing Power
The company faced increased raw material and packing input costs in March 2026, partly due to geopolitical events and crude oil price volatility, which impacted gross margins. Logistics disruptions, including container shortages and shipping route issues, also posed challenges. However, management has implemented alternative shipping routes and maintains that the company can pass on input cost increases to customers due to flexible pricing arrangements, mitigating margin pressure.
Operational Efficiency and Working Capital
Sanjivani Paranteral Limited has improved its debtor days from 90 days last year to 65-70 days in FY26, with a target to further reduce them to 55-60 days in the coming periods. This reflects better working capital management. The company emphasizes its long-standing customer relationships, focus on quality, and efficient turnaround times as key differentiators in the competitive pharmaceutical market, which has helped maintain a stable base business.